EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities

por Yedier-Bayram, Ozlem, Gokbayrak, Bengul, Kayabolen, Alisan, Aksu, Ali Cenk, Cavga, Ayse Derya, Cingöz, Ahmet, Kala, Ezgi Yagmur, Karabiyik, Goktug, Günsay, Rauf, Esin, Beril, Morova, Tunc, Uyulur, Fırat, Syed, Hamzah, Philpott, Martin, Cribbs, Adam P., Kung, Sonia H. Y., Lack, Nathan A., Onder, Tamer T., Bagci-Onder, Tugba
Publicado 2022

Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival

por Ozyerli-Goknar, Ezgi, Kala, Ezgi Yagmur, Aksu, Ali Cenk, Bulut, Ipek, Cingöz, Ahmet, Nizamuddin, Sheikh, Biniossek, Martin, Seker-Polat, Fidan, Morova, Tunc, Aztekin, Can, Kung, Sonia H. Y., Syed, Hamzah, Tuncbag, Nurcan, Gönen, Mehmet, Philpott, Martin, Cribbs, Adam P., Acilan, Ceyda, Lack, Nathan A., Onder, Tamer T., Timmers, H. T. Marc, Bagci-Onder, Tugba
Publicado 2023